Abstract
Amaç: Çalışmamızda, ileri evre küçük hücreli dışı akciğer karsinomlu hastalarda tedavi öncesi prognostik faktörlerin sağkalım üzerine etkilerini değerlendirmeyi amaçladık. Hastalar ve Yöntem: Şubat 2004 - Aralık 2006 tarihleri arasında kliniğimize başvurmuş evre IV küçük hücreli dışı, kemoterapi almış olan 73 hasta retrospektif olarak değerlendirildi. Bulgular: Performansı sıfır, 65 yaşından daha genç hastaların yaşam süreleri diğerlerine göre anlamlı olarak uzun bulunurken, histopatolojik alt grup, sigara içimi, kilo kaybı ve cinsiyet farkının yaşam süresi üzerinde anlamlı bir etkisi yoktu p>0.05 . Metastaz varlığı ile sağkalım süresi karşılaştırıldığında, istatistiksel olarak anlamlı bir fark saptanmamıştır. LDH seviyesi yüksek olanların yaşam süresinin daha kısa olduğu görüldü. Sonuç: 65 yaştan genç olmak, performansın iyi olması, normal LDH düzeyi ileri evre küçük hücreli dışı akciğer kanserli olguların uzun yaşam süresinde önemli rol oynar.
References
- Okamoto T, Maruyama R, Shoji F, et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005;47:85-91.
- Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
- Halilçolar H, Tatar D, Ertuğrul E ve ark. Akciğer Kanseri, Multidisipliner Yaklaşım. Ankara: Bilimse Tıp Yayınevi; 1999:17-22.
- Fu XL, Zhu XZ, Shi DR et al. Study of prognostic predictors for nonsmall cell lung cancer. Lung Cancer 1999;23:143-52.
- Wagner H Jr. Rational integration of radiation and chemotheraphy in patients with unresectable stage IIIA or IIIB NSCLC. Result from Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Theraphy Oncology Group. Chest 1993;103:35-42.
- Wigren T. Confi rmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997;44:9-15.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
- Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non -small cell lung cancer. Chest 2003;123:226S-243S.
- Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural eff usion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50.
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
- Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-92.
- Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algori thms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-30.
- Songür N, Kuru B, Ok U. İleri evre kü çük hücreli olmayan akciğer kanserlerinde sağkalımı etkileyen prognostik faktörler. Toraks Dergisi 2005;6:91- 7.
- Luketich JD, Burt ME. Does res ection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg 1996;62:1614-6.
- Schuchert MJ, Luketich JD. Solitary sites of metastatic disease in n on-small cell lung cancer. Curr Treat Options Oncol 2003;4:65-79.
- Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced n on-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992;30:1-6.
- Charloux A, Hedelin G, Dietemann A, et al. Prognostic valu e of histology in patients with non-small cell lung cancer. Lung Cancer 1997;17:123-34.
Abstract
Purpose: In this study, we aimed to evaluate the effects of the prognostic factors on the survival rate of advanced stage non-small cell lung cancer cases. Patients and Methods: In this study, we aimed to evaluate the effects of the prognostic factors on the survival rate of stage IV non-small cell lung cancer cases. Results: Younger then 65 years old, with 0 performance patients surviving rates are significantly longer than others. On the other side that bien histopatholgical subgroup, smoking, weight loss or sexual differences had no afeect on the survival rate p>0.05 . When we compare the presence of metastases and survival rate there was no significant differences. When LDH levels were high surviving rates were lower. Conclusion: Normal LDH levels, good performance status and
Keywords
References
- Okamoto T, Maruyama R, Shoji F, et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005;47:85-91.
- Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
- Halilçolar H, Tatar D, Ertuğrul E ve ark. Akciğer Kanseri, Multidisipliner Yaklaşım. Ankara: Bilimse Tıp Yayınevi; 1999:17-22.
- Fu XL, Zhu XZ, Shi DR et al. Study of prognostic predictors for nonsmall cell lung cancer. Lung Cancer 1999;23:143-52.
- Wagner H Jr. Rational integration of radiation and chemotheraphy in patients with unresectable stage IIIA or IIIB NSCLC. Result from Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Theraphy Oncology Group. Chest 1993;103:35-42.
- Wigren T. Confi rmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997;44:9-15.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
- Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non -small cell lung cancer. Chest 2003;123:226S-243S.
- Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural eff usion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50.
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
- Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-92.
- Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algori thms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-30.
- Songür N, Kuru B, Ok U. İleri evre kü çük hücreli olmayan akciğer kanserlerinde sağkalımı etkileyen prognostik faktörler. Toraks Dergisi 2005;6:91- 7.
- Luketich JD, Burt ME. Does res ection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg 1996;62:1614-6.
- Schuchert MJ, Luketich JD. Solitary sites of metastatic disease in n on-small cell lung cancer. Curr Treat Options Oncol 2003;4:65-79.
- Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced n on-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992;30:1-6.
- Charloux A, Hedelin G, Dietemann A, et al. Prognostic valu e of histology in patients with non-small cell lung cancer. Lung Cancer 1997;17:123-34.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Research Article |
| Authors | |
| Publication Date | June 1, 2011 |
| Published in Issue | Year 2011Issue: 2 |